Treatment of endometriosis with the GnRH agonist nafarelin acetate.
Additional details of a multicenter study of nafarelin acetate with particular attention to a unique endometriosis scoring system utilized are reviewed. Additional information regarding the relapse of symptoms of 10 patients treated with nafarelin and danazol during a 6- to 12-month follow-up interval is described. Transient decreases in leukocytes previously reported by other investigators were observed in 3 of 8 patients, but appear to represent a laboratory artifact.
Jacobs
L A
LA
Mayo Graduate School of Medicine, Rochester, Minnesota.
Field
C S
CS
Thie
J L
JL
Coulam
C B
CB
D000293:Adolescent; D000328:Adult; D003613:Danazol / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D017274:Nafarelin; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol